The BRPF3 Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-mediated gene-disrupted population in Jurkat cells, in which the scaffold protein BRPF3 is targeted for loss-of-function. This polyclonal knockout cell pool offers a genetically heterogeneous model to interrogate BRPF3-dependent processes without selection of individual clones, making it suitable for studying its roles in histone acetylation and transcriptional regulation.
Jurkat cells, derived from human T cell leukemia, are an established model for T cell signaling, apoptosis, and lymphocytic biology. Their rapid proliferation and well-characterized signal transduction pathways, including T cell receptor responses, make them a versatile platform for probing epigenetic regulators that influence leukemogenesis and immune function.
BRPF3 functions as an essential scaffold within the HBO1 histone acetyltransferase complex, where it assembles with KAT7 (also known as HBO1 or MYST2), ING5, members of the JADE family (JADE1, JADE2, JADE3), and MEAF6. This multiprotein complex catalyzes the acetylation of histone H4 at specific lysine residues (K5, K8, K12), a modification that relaxes chromatin structure and facilitates transcriptional activation, as well as regulating DNA replication by licensing origins. Targeted disruption of BRPF3 compromises the stability and function of the HBO1 complex, resulting in decreased global H4 acetylation and reprogramming of gene expression networks. Although the upstream regulatory inputs controlling BRPF3 expression or stability are not well characterized, potential involvement of transcription factors that govern HAT complex assembly may exist. Within the pathway, BRPF3 acts downstream of KAT7 catalytic activity, yet it provides structural integrity; its loss-of-function can thus indirectly diminish histone acetylation and downstream transcriptional events.
In Jurkat cells, which represent a model for T cell acute lymphoblastic leukemia, perturbing BRPF3 may reveal how aberrant histone acetylation contributes to oncogenic transcriptional states. Since the HBO1 complex influences replication origin firing and gene expression, knockout cells enable dissection of epigenetically driven vulnerabilities in leukemic T cells, potentially identifying targets for therapeutic intervention in cancers with epigenetic dysregulation.
Researchers can employ this polyclonal knockout model in a wide range of experimental settings, from basic chromatin biology to preclinical drug discovery. Representative applications include performing Western blotting with antibodies specific to histone H4 acetylation marks (H4K5ac, H4K8ac, H4K12ac) to confirm the biochemical impact of BRPF3 disruption, and RNA sequencing to capture transcriptome-wide changes associated with loss of HBO1 complex function. Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) enables locus-specific assessment of histone modification alterations. Functional assays such as proliferation, viability measurements, and flow cytometry-based cell cycle profiling can link epigenetic perturbations to T cell biology phenotypes. These cells are particularly suited for studying epigenetic dysregulation in T cell leukemia, the role of histone acetylation in chromatin remodeling, and the validation of BRPF3 as a potential therapeutic target in cancer. For further information, please contact Ascent Research.
